Dumping Amylin ups stakes for Lilly

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. divorced one diabetes darling in favor of a new flame last week, but no analysts cheered. And a few booed.

Lilly and its San Diego-based partner Amylin Pharmaceuticals Inc. decided to go their separate ways, with Amylin agreeing to pay Lilly to gain full rights to the diabetes medicines Byetta and Bydureon.

Lilly will instead focus on its new diabetes drug Tradjenta, which was developed by Germany-based Boehringer Ingelheim GmbH, as well as three others Lilly and Boehringer are developing together.

The move puts ever more pressure on Lilly’s pipeline to deliver new drugs—something it has struggled mightily to do ever since the approval of Byetta in 2005.

“In our view, today’s news represents yet another pipeline disappointment for LLY,” wrote Jami Rubin, a pharmaceutical analyst for Goldman Sachs Group Inc. She acknowledged that the deal gives Lilly more flexibility than it appeared to have, given the legal contention with Amylin.

“However,” she added, “LLY’s outlook now rests even more on the rest of its pipeline, for which we have seen minimal data.”

The break-up comes after Amylin sued Lilly unsuccessfully this year to force it to use separate sales forces for Byetta and Tradjenta, saying the drugs would compete against each other. Amylin had vowed to keep fighting Lilly even after a federal judge ruled in Lilly’s favor.

The divorce also comes just months before Bydureon’s expected approval in the United States (it was approved earlier this year in Europe). And that spooked investors in Amylin, who traded down the company’s stock price 11 percent on Nov. 8, the day the break-up was announced.

"Did AMLN Just Take Control of a Sinking Ship?” was the title of Collins Stewart analyst Salveen Richter’s report on the deal, which referred to Amylin by its ticker symbol. With the U.S. Food and Drug Administration scheduled to render a ruling on Bydureon on Jan. 28, he wondered if Lilly’s willingness to let go of the product signals that the company has low expectations for its potential.

Byetta was the first of a new series of drugs called glucagon-like peptides, or GLP-1s. Bydureon is based on the same drug compound, exenatide, but is supposed to be more convenient, since it requires an injection only once a week instead of twice a day, as Byetta does.

But in the meantime, Denmark-based Novo Nordisk A/S has launched its own GLP-1, called Victoza, which in clinical trials has shown better results at lowering diabetics’ blood sugar levels than either Byetta or Bydureon. Those developments, as well as FDA concerns about Byetta's contributing to pancreatitis in some patients, have dampened Byetta sales as well as expectations for Bydureon.

Through the first nine months of this year, Byetta and Bydureon recorded worldwide sales of $508 million, down 5 percent from the same period a year earlier.

In its deal with Boehringer Ingelheim, signed in January, Lilly got rights to Tradjenta, an oral diabetes medication, a type that has proved popular with patients. Lilly is also developing another GLP-1, called dulaglutide, which is soon to enter Phase 3 clinical trials and could reach the market within a few years.

Lilly investors largely shrugged about the break-up with Amylin, since Lilly will get a $250 million upfront break-up fee, and royalties up to $1.2 billion over the life of Byetta, Bydureon and one other medicine the two companies were developing.

“Given the comments from LLY, we view this as an essentially neutral financial development for the company,” wrote Deutsche Bank analyst Barbara Ryan, in a Nov. 8 note to investors, referring to LLY by its ticker symbol.

Other analysts thought the deal might be a slight negative for Lilly, but emphasized that clearing up the cloud of litigation is a good thing.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ
  1. Here are a few candidates for this new group, "ripped from the headlines." First up, that bizzaro State Senator Brent Waltz; secondly, the unethical Todd Huston, and his contractual arrangements scheme; Finally, but not least of all, the dishonorable Eric Turner. What sayeth you Greg Zoeller?

  2. Good day. I can't hide this great testimony that take place in my life I will love everyone to know it and be partaker that is why I always place it on answer, I am Mrs,Natalie Cuttaia by name, I live in Texas, United State Of America, I want to thank (Mr.Bruce Brandon) for his kindness upon my family life. I never knew that there is still nice lender like this on internet and earth here. Just some Months Back, I was in search for a loan of $100,000,00 as I was running out of money for feeding and rent. I was scammed $6,800 Dollars and I decided not to involve my self in such business again but a Friend of my introduced me to a loan firm due to my appearance and doings. And I told him that I am not interested of any loan deal anymore but he told me that there is still a nice lender who he will recommend me to, and I made a trial and I am most grateful lucky am I today, I was given a loan amount of $100,000.00usd, by this great Company (Bruce Brandon Loan Company) managed by (Mr.Bruce Brandon) If you are in need of a genuine or legit loan or financial assistance and you can be reliable and trusted of capable of paying back at the due time of the funds I will advice you to, contact him via: ( bruce.brandon071@gmail.com ) And you will be free from scams in the internet. All thanks to Mr.Bruce Brandon You are the one who remove me and my family out of poverty. The reason why i am doing this is that, i promise Mr.Bruce Brandon that if i truly got my loan, i will advertize his company and bring customers to his company. Contact him via ( bruce.brandon071@gmail.com )for the Loan you have been looking for..

  3. Hello, We are firm Organization formed to help people in needs of helps,such as financial help. So if you are going through financial difficulty or you are in any financial mess,and you need funds to start up your own business,or you need loan to settle your debt or pay off your bills,start a nice business, or you are finding it hard to obtain capital loan from local banks,contact us today via email mrsroseberrywilkinsfunds.usa@gmail.com So do not let these opportunity pass you by because Jesus is the same yesterday, today and forever more. Please these is for serious minded and God fearing People. Your Name: Loan Amount: Loan Duration: Valid Cell Phone Number: Thanks for your understanding to your contact as we Await Regards Management Email:mrsroseberrywilkinsfunds.usa@gmail.com

  4. The question is, where could they build a new stadium? It seems in the past year, all the prime spots have been spoken for with potential projects. Maybe in the industrial wasteland area a block past Lucas Oil? I think it needs to be close to the core, if a new stadium is built.

  5. Aldi is generally a great shopping experience. Still, I'm sure YOU wouldn't want to shop there, which I consider a positive.